Novo Nordisk A/S (NYSE:NVO) Shares Sold by LPL Financial LLC

LPL Financial LLC decreased its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 0.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,356,067 shares of the company's stock after selling 6,715 shares during the period. LPL Financial LLC's holdings in Novo Nordisk A/S were worth $116,594,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Daiwa Securities Group Inc. bought a new stake in Novo Nordisk A/S during the third quarter valued at approximately $28,000. Center for Financial Planning Inc. boosted its stake in Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after buying an additional 123 shares during the period. Dunhill Financial LLC boosted its stake in shares of Novo Nordisk A/S by 196.8% during the 3rd quarter. Dunhill Financial LLC now owns 469 shares of the company's stock worth $56,000 after purchasing an additional 311 shares during the period. Albion Financial Group UT grew its position in Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company's stock valued at $44,000 after acquiring an additional 278 shares during the last quarter. Finally, Hager Investment Management Services LLC bought a new position in shares of Novo Nordisk A/S during the 4th quarter worth $46,000. Institutional investors own 11.54% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an "equal weight" rating on the stock. BNP Paribas raised shares of Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, December 2nd. BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating for the company in a research note on Monday, December 23rd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research note on Monday, January 6th. Finally, UBS Group upgraded Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $145.25.

Remove Ads

Novo Nordisk A/S Trading Down 2.6 %

NYSE:NVO traded down $1.89 during trading hours on Thursday, reaching $69.84. 4,192,295 shares of the stock were exchanged, compared to its average volume of 8,427,408. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $313.43 billion, a price-to-earnings ratio of 21.23, a PEG ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a twelve month low of $69.79 and a twelve month high of $148.15. The business has a 50-day moving average of $82.78 and a two-hundred day moving average of $99.75.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a $0.7874 dividend. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S's payout ratio is 47.72%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.